These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
667 related articles for article (PubMed ID: 22310605)
1. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes. Foster CE; Weng RR; Piper M; Laugenou K; Ichii H; Lakey J; Malinoski D Transplant Proc; 2012 Jan; 44(1):164-6. PubMed ID: 22310605 [TBL] [Abstract][Full Text] [Related]
2. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study. Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function. Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641 [TBL] [Abstract][Full Text] [Related]
4. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up. Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733 [TBL] [Abstract][Full Text] [Related]
5. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. Flaman F; Zieroth S; Rao V; Ross H; Delgado DH J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501 [TBL] [Abstract][Full Text] [Related]
6. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction. Patel SJ; Duhart BT; Krauss AG; Moore LW; Egidi MF; Amiri HS; Gaber LW; Gaber AO Transplantation; 2008 Jul; 86(2):313-20. PubMed ID: 18645496 [TBL] [Abstract][Full Text] [Related]
7. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D; N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248 [TBL] [Abstract][Full Text] [Related]
8. Comparison of efficacy and safety between rabbit anti-thymocyte globulin and anti-T lymphocyte globulin in kidney transplantation from donation after cardiac death: a retrospective cohort study. Chen GD; Lai XQ; Ko DS; Qiu J; Wang CX; Han M; Li J; Huang G; He XS; Chen LZ Nephrology (Carlton); 2015 Aug; 20(8):539-43. PubMed ID: 25808082 [TBL] [Abstract][Full Text] [Related]
9. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study. Gentile G; Somma C; Gennarini A; Mastroluca D; Rota G; Lacanna F; Locatelli B; Remuzzi G; Ruggenenti P Am J Nephrol; 2015; 41(1):16-27. PubMed ID: 25612603 [TBL] [Abstract][Full Text] [Related]
10. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin. Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269 [TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants. Lentine KL; Schnitzler MA; Xiao H; Brennan DC Trials; 2015 Aug; 16():365. PubMed ID: 26285695 [TBL] [Abstract][Full Text] [Related]
12. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome. Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376 [TBL] [Abstract][Full Text] [Related]
13. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age. Patel SJ; Knight RJ; Suki WN; Abdellatif A; Duhart BT; Krauss AG; Mannan S; Nezakatgoo N; Osama Gaber A Clin Transplant; 2011; 25(3):E250-6. PubMed ID: 21231963 [TBL] [Abstract][Full Text] [Related]
14. Induction Therapy With ATG Compared With Anti-IL2 Basiliximab in Low-Immunologic Risk Kidney Transplant Recipients. Dedinská I; Graňák K; Vnučák M; Skálová P; Laca Ĺ; Krivuš J; Galajda P; Mokáň M Transplant Proc; 2019 Dec; 51(10):3259-3264. PubMed ID: 31732198 [TBL] [Abstract][Full Text] [Related]
15. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. Carrier M; Leblanc MH; Perrault LP; White M; Doyle D; Beaudoin D; Guertin MC J Heart Lung Transplant; 2007 Mar; 26(3):258-63. PubMed ID: 17346628 [TBL] [Abstract][Full Text] [Related]
17. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Deeks ED; Keating GM Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926 [TBL] [Abstract][Full Text] [Related]